

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/110460 A1

(51) International Patent Classification⁷: A61K 31/58,
31/167, 9/12 // (A61K 31/58, 31:167)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(21) International Application Number:
PCT/EP2004/051067

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 9 June 2004 (09.06.2004)

(25) Filing Language: English

(26) Publication Language: English

Declarations under Rule 4.17:

(30) Priority Data:
03013510.7 13 June 2003 (13.06.2003) EP

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

(71) Applicant (for all designated States except US): ALTANA
PHARMA AG [DE/DE]; Byk-Gulden-Str. 2, 78467 Kon-
stanz (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DIETZEL, Klaus
[DE/DE]; Thingoltstr. 2e, 78465 Konstanz (DE).
MUELLER, Helgert [DE/DE]; Zum Lerchental 1a,
78315 Radolfzell (DE).

(74) Agent: KRATZER, Bernd; c/o ALTANA Pharma AG,
Byk-Gulden-Str. 2, 78467 Konstanz (DE).

— of inventorship (Rule 4.17(iv)) for US only

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 2004/110460 A1

(54) Title: FORMOTEROL AND CICLESONIDE COMBINATION

(57) Abstract: This invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.

Formoterol and Ciclesonide Combination


Field of the Invention

This invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.

Background

Formoterol which is the compound N-[2-hydroxy-5-(1-hydroxy-2-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl) phenyl] formamide, is known from US 3994974. It is known to be a bronchodilator and used in the treatment of inflammatory or obstructive airways diseases.

GB 247680 discloses pregna-1,4-diene-3,20-dione-16-17-acetal-21 esters and their use in the treatment of inflammatory conditions. The compounds have the general structure:



Formula I

wherein R1 is 2-propyl, 1-butyl, 2-butyl, cyclohexyl or phenyl; and R2 is acetyl or isobutanoyl. Ciclesonide is the INN for a compound of formula I in which R1 is cyclohexyl and R2 is isobutanoyl with the chemical name [11 β ,16 α (R)]-16,17-[(Cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-dien-3,20-dion .

This compound has undergone evaluation as an antiasthmatic and pharmacokinetic studies show that it will be useful in an inhaler formulation. Ciclesonide is only moderately absorbed after oral administration and has low systemic activity. Concentration of the drug in the lungs is high and metabolism by liver oxidases is very high, giving the drug a low plasma half-life. Systemic activity of ciclesonide is three times lower than that of budesonide, but anti-inflammatory activity is higher for the former.

DE 19541689 is related to the combined use of ciclesonide with a β_2 -sympathomimetic, for the treatment of disorders of the respiratory tract. As an example a metered dose aerosol composition comprising ciclesonide and formoterol in trichlorofluoromethane (R11) as propellant is disclosed.


EP-A-0504112 discloses examples of pharmaceutical compositions for aerosol use comprising formoterol fumarate.

WO 93/11747 discloses a pharmaceutical suspension formulation suitable for aerosol administration, consisting essentially of a therapeutically effective amount of a drug and a propellant selected from the group consisting of HFA 134a, HFA 227, and a mixture thereof, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug. The application specifically discloses formulations of formoterol fumarate in HFA 134a, HFA 227 and 1:1 mixtures of HFA 134a and HFA 227.

WO 93/11745 discloses pharmaceutical aerosol formulations, substantially free of surfactant containing fluorocarbon or hydrogen-containing chlorofluorocarbon propellants and up to 5% of a polar co-solvent. Preferred propellants are HFA 134a and HFA 227, which are preferably used alone. The preferred polar co-solvent is ethanol and it is stated that in general only small quantities e.g. 0.05 to 3.0% w/w of polar co-solvent are required to improve the dispersion and the use of quantities in excess of 5% w/w may disadvantageously tend to dissolve the medicament.

WO 97/47286 discloses a pharmaceutical suspension formulation suitable for aerosol administration, consisting essentially of: (a) from 0.0025 to 0.1% w/w of micronized formoterol, or an acid addition salt thereof and (b) from 0.1 to 5.0% w/w ethanol, (c) HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a and optionally (d) a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug. The application specifically discloses formulations comprising formoterol fumarate dispersed in HFA 134a, HFA 227 or mixtures thereof and 1 to 3% ethanol. It is stated that it is important to ensure the formoterol fumarate does not come into contact with high concentrations e.g. above 10% w/w, of ethanol since the drug would dissolve leading to instability and crystal growth problems in the final formulation and that the maximum concentration of ethanol during formulation is preferably less than 5%. It is stated that aerosol compositions consisting of formoterol fumarate, HFA 134a and ethanol have proved to be extremely sensitive to ethanol concentration and an ethanol concentration of 3.5% w/w may cause unacceptable crystal growth.

WO 98/52542 discloses a pharmaceutical compositions comprising a therapeutically effective amount of a compound of the formula (I):



Formula I

wherein R1 is 2-propyl, 1-butyl, 2-butyl, cyclohexyl or phenyl; and R2 is acetyl or isobutanoyl and a hydrofluorocarbon propellant, preferably selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and cosolvent, preferably ethanol, in an amount effective to solubilize the compound of formula (I) and optionally a surfactant. The application specifically discloses solution formulations comprising ciclesonide (1 to 5 mg/ml) in HFA 134a, HFA 227 or mixtures of HFA 134a and HFA 227 and 5 to 20% by weight ethanol.

Despite the various approaches used in formulating drugs for use in aerosol inhalation, a number of serious difficulties and uncertainties are still often encountered in attempting to develop a physically and chemically stable HFA 134a and/or HFA 227 based formulation that reliably delivers an accurate dose of drug having the proper particle size range. In particular formoterol is reported to be very sensitive in HFA 134a and/or HFA 227 propellant. Up to date no medicinal aerosol formoterol product based on HFA technology is available on the market.

Summary of the Invention

There is a need for a HFA 134a and/or HFA 227 based medicinal aerosol product containing formoterol and ciclesonide that is chemically and physically stable and that is suitable for delivery to the respiratory system of a patient.

Surprisingly it has been found that it is possible to provide physically and chemically stable formulations suitable for aerosol administration comprising therapeutically effective amounts of formoterol and ciclesonide in suspension in HFA 134a and/or HFA 227 propellant.

Accordingly in one aspect of the present invention there is provided a pharmaceutical suspension formulation suitable for aerosol administration comprising particles of micronized formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

Preferred formulations according to the invention exhibit substantially no growth in particle size or change in crystal morphology of the formoterol and/or ciclesonide over a prolonged period, are readily redispersible, and upon redispersion do not flocculate so quickly as to prevent reproducing dosing of ciclesonide and/or formoterol.

In addition to stability the formulations according to the invention provide a significant unexpected therapeutic benefit, particularly a synergistic therapeutic benefit, in the treatment of inflammatory or obstructive airways diseases. In particular, it has been found that compositions containing ciclesonide and formoterol induce an anti-inflammatory activity which is significantly greater than that induced by ciclesonide and formoterol alone and that the amount of ciclesonide needed for a given anti-inflammatory effect may be significantly reduced when used in admixture with formoterol, thereby reducing the risk of undesirable side effects from the repeated exposure to the steroid involved in the treatment of inflammatory or obstructive airways diseases. Furthermore, using the compositions of the invention, pharmaceutical compositions, which have a rapid onset and a long duration of action may be prepared. In particular the combination therapy according to the inventions permits the establishment of a twice daily, in particular once daily dosing regimen with consequent substantial benefits in, for example the treatment of obstructive or inflammatory airways diseases (e.g. higher patient compliance, less side effects).

Ciclesonide (hereinafter also referred to as active ingredient) is the INN for a compound with the chemical name [11 β ,16 α (R)]-16,17-[(Cyclohexylmethyl)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-dien-3,20-dion. Ciclesonide and its preparation are disclosed in DE 4129535. Ciclesonide as used herein also includes, pharmaceutically acceptable salts of ciclesonide, solvates of ciclesonide, physiologically functional derivatives of ciclesonide or solvates thereof. By the term "physiologically functional derivative" is meant a chemical derivative of ciclesonide having the same physiological function as ciclesonide, for example, by being convertible in the body thereto or by being an active metabolite of ciclesonide. Physiological functional derivatives of ciclesonide which may be mentioned in connection with the invention are for example the 21-hydroxy derivative of ciclesonide with the chemical name 16 α ,17-(22R,S)-Cyclohexylmethylenedioxy-11 β ,21-dihydroxypregna-1,4-dien-3,20-dion, in particular 16 α ,17-(22R)-Cyclohexylmethylenedioxy-11 β ,21-dihydroxypregna-1,4-dien-3,20-dion. This compound and its preparation are disclosed in WO 94/22899.

Formoterol (hereinafter also referred to as active ingredient) is the compound N-[2-hydroxy-5-(1-hydroxy-2-(2-(4-methoxyphenyl)-1-methylethyl) amino)ethyl) phenyl] formamide, and is disclosed in US 3994974. Formoterol as used herein also includes, pharmaceutically acceptable salts of formoterol, solvates of formoterol, physiologically functional derivatives of formoterol or solvates thereof. As would be appreciated by the skilled person, formoterol may exist in form of different stereoisomers. The present invention includes all stereoisomers of formoterol either in substantially pure form or admixed in any proportions. In one embodiment of the invention, formoterol is present in the formulations according to the invention essentially as R,R-formoterol. Essentially as R,R-formoterol in connection with the present inventions refers to a ratio of R,R-formoterol in a mixture of stereoisomers of formoterol of at least 95%, preferably at least 99%. Stereoisomers of formoterol are for example disclosed in WO98/21175, WO 99/17754, US 6068833 and US 5795564. By the term "physiologically functional derivative" is meant a chemical derivative of formoterol having the same physiological function as the free compound, for example, by being convertible in the body thereto. Suitable salts according to the invention include those formed with both organic and inorganic acids. Pharmaceutically acceptable acid addition salts include but are not limited to those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic, isethionic, and naphthalenecarboxylic, such as 1-hydroxy-2-naphthalenecarboxylic acids. Formoterol fumarate and R,R-formoterol fumarate are preferably mentioned in connection with the invention.

As mentioned above, both ciclesonide and formoterol and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have been described for use in the treatment of respiratory diseases. Therefore, formulations of ciclesonide and formoterol and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have use in the prophylaxis and treatment of clinical conditions for which a selective β_2 -adrenoreceptor agonist and/or a glucocorticosteroid is indicated. Such conditions include diseases associated with reversible airways obstruction such as asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD) (e. g. chronic and wheezy bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e. g. rhinitis, such as allergic and seasonal rhinitis).

Accordingly, the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective β_2 -adrenoreceptor agonist and/or glucocorticosteroid is indicated, which comprises administration of a therapeutically effective amount of a pharmaceutical formulation according to the invention comprising formoterol or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof and ciclesonide or a pharmaceutical acceptable salt, solvate, or physiologically functional derivative thereof. In particular, the present invention provides such a method for the prophylaxis or treatment of a disease associated with reversible airways obstruction such

as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.

The amount of formoterol and ciclesonide, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the subject under treatment, and the particular disorder or disease being treated. As a monotherapy, formoterol fumarate is generally administered to adult humans by aerosol inhalation at a dose of 6 μ g to 12 μ g (corresponding to 4.9 μ g to 9.8 μ g formoterol) twice daily or up to 24 μ g twice daily. As a monotherapy, ciclesonide is generally administered to adult humans by inhalation at a daily dose of from 0,05mg to 1,6mg, which can be administered in one or several doses.

It is preferred in connection with the present invention to have a twice daily dosing regimen. Surprisingly it has been found that formoterol in combination with ciclesonide may be effectively administered as a once daily dosing regimen. Further subject of the invention therefore is also combination of ciclesonide with formoterol in the form of once daily dosing regimen.

Suitably, the pharmaceutical formulations which are suitable for inhalation according to the invention comprise the active ingredients in amounts such that in case of administration by inhalation from inhalers each actuation provides a therapeutically effective dose, for example, a dose of formoterol fumarate of 4 μ g to 24 μ g, preferably 6 μ g to 12 μ g and a dose of ciclesonide of 10 μ g to 1600 μ g, preferably 40 μ g to 800 μ g, more preferably, 50 μ g to 400 μ g. It is particularly preferred that each actuation provide a dose therapeutically effective for a twice daily dosing regimen or more particularly preferred for a once daily dosing regimen.

Pharmaceutical formulations according to the invention, depending on the valve chamber to be used, may suitably contain from about 0.2mg to about 8mg ciclesonide per ml, preferably from 1mg to 4mg per ml. Ciclesonide may be formulated in different strength of doses e.g. 1mg per ml, 2mg per ml or 4mg per ml. Formoterol may be present in the formulations according to the inventions from about 0.04mg to 0.5mg formoterol per ml, preferably from 0.09mg to 0,4mg formoterol per ml and may be formulated in different strength doses as well.

The pharmaceutical formulations according to the invention may further include other therapeutic agents for example anticholinergics such as ipatropium and tiotropium, pharmaceutically acceptable salts salts or solvents thereof. Examples, which may be mentioned are ipatropium bromide and tiotropium bromide and solvates thereof.

Suitably, the pharmaceutical formulations which are suitable for inhalation according to the invention provide therapeutically effective doses that permit the establishment of a twice daily (bis in diem – b. i. d) dosing regimen and in particular a once daily dosing regimen.

Suspension aerosol formulation refers to a formulation in which the drug is in particulate form and is substantially insoluble in the formulation.

Propellant systems for aerosol formulations based on HFA 134a (1, 1, 1, 2-tertrafluorethane) and HFA 227 (1, 1, 1, 2, 3, 3, 3-heptafluoropropane) are disclosed in, for example, EP 0372777, W091/04011, W091/11173, W091/11495, W091/14422, W093/11743, and EP-0553298. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome problems associated with the use of this new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared. The applications propose, for example, the addition of one or more of excipients such as polar cosolvents or wetting agents (e.g. alcohols such as ethanol), alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids such as oleic acid, polyethoxylates etc.) or bulking agents such as a sugar (see for example WO02/30394) and vehicles such as salts of cromoglicic acid and/or nedocromil which are contained at concentrations, which are not therapeutically and prophylactically active (see WO00/07567).

The formulations according to the invention may contain additional excipients as mentioned above.

In a preferred embodiment of the invention the formulations contain a wetting agent, preferably ethanol and optionally a surfactant, preferably oleic acid. The presence of the ethanol assist in the stability, the general performance and in the manufacturing of the formulation. Ethanol is preferably present in concentration range, which does not lead to dissolution of the ciclesonide in the propellant formulation and does not cause undesired effects on formoterol. Preferably ethanol is present in the formulations according to the invention below 3% (w/w), more preferably below 2%, particularly preferable below 1%, and most preferably below 0.5%.

The aerosol formulations according to the invention may preferably contain surfactant. Suitable surfactants are known in the art and include oleic acid, sorbitantriolate and lecithin. A preferred surfactant is oleic acid. The amount of surfactant, which may be present in the formulation according to the invention is usually in the range of about 0.001% to 0.1% (w/w).

In another embodiment the formulations according to the invention additionally contain a bulking agent and/or vehicle. Examples of bulking agents which may be mentioned in connection with the invention are sugar (such as lactose, lactose monohydrate, glucose, D+ trehalose dehydrate), DL-alanine and/or ascorbic acid. Suitable bulking agents are also disclosed in WO02/30394. The weight ratio of active ingre-

dient (ciclesonide and formoterol) to bulking agent is generally in the range of 1:0.1 to 1:100, preferably 1.3 to 1:40. The bulking agent is preferably present in micronized form with a mean particle size diameter of less than 100 microns, desirably less than 20 microns, and preferably in the range 1 to 10 microns, for example, 1 to 5 microns. In a preferred embodiment the mean particle size diameter is below 1 micron such as described in WO02/30394.

In another embodiment of the invention the formulations according to the inventions additionally contain vehicles such as pharmaceutically acceptable salts of cromoglicic acid and/or nedocromil which are contained at concentrations, which are not therapeutically and prophylactically active (see WO00/07567). In a preferred embodiment the salt of cromoglicic acid is the disodium salt (disodium chromoglycate) and the salt of nedocromil is the sodium salt. These vehicles are generally present in the range of 10:1 to 1:10 by weight based on the weight of the active ingredients. These vehicles are also present preferably in micronized form with a mean particle size diameter of preferably less than 10 microns. However they may also be present with greater particle sizes.

The active ingredients (ciclesonide and formoterol respectively) present as particles in the formulations according to the invention should be in a form so as to permit inhalation of substantially all of the active ingredients into the lungs upon administration of the aerosol formulation. Thus the active ingredients should -unless obtainable by chemical processes in a suitable size- be micronized so as to permit inhalation of substantially all of the active ingredients into the lungs upon administration of the aerosol formulation. Thus the active ingredients will have a mean particle size diameter of less than 100 microns, desirably less than 20 microns, and preferably in the range 1 to 10 microns, for example, 1 to 5 microns.

The formulations according to the invention may be prepared by adding the required quantity of active ingredients into an aerosol vial, crimping a valve on the vial and introducing propellant or optionally a pre-mixed blend of propellant and optionally further excipients such as surfactant through the valve. Alternatively the active ingredients may be added to a chilled propellant or optionally a pre-mixed blend of propellant and optionally further excipients and dispersed using a suitable mixer. After homogenisation the suspension can be filled into aerosol vials and the vial closed by crimping a valve on the vial.

Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant, such as plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. It may be preferred that canisters be coated with a fluorocarbon polymer as described in WO 96/32150, for example, a co-polymer of polyethersulphone (PES) and polytetrafluoroethylene (PTFE). Another polymer for coating that may be contemplated is FEP (fluorinated ethylene propylene).

The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Thermoplastic elastomer valves as described in W092/11190 and valves containing EPDM rubber as described in W095/02650 are especially suitable. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (eg. DF10, DF30, DF60), Bepak pic, UK (eg. BK300, BK356, BK357) and 3M-Neotechnic Ltd, UK (eg. Spraymiser).

Valve seals, especially the gasket seal and also the seals around the metering chamber, will preferably be manufactured of a material, which is inert to and resists extraction into the contents of the formulation, especially when the contents include ethanol.

Valve materials, especially the material of manufacture of the metering chamber, will preferably be manufactured of a material which is inert to and resists distortion by contents of the formulation, especially when the contents include ethanol. Particularly suitable materials for use in manufacture of the metering chamber include polyesters eg polybutyleneterephthalate (PBT) and acetals, especially PBT.

Materials of manufacture of the metering chamber and/or the valve stem may desirably be fluorinated, partially fluorinated or impregnated with fluorine containing substances in order to resist drug deposition.

Valves, which are entirely or substantially composed of metal components (eg Spraymiser, 3M-Neotechnic), are especially preferred for use according to the invention.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question. Furthermore, the claimed formulations include bioequivalents as defined by the US Food and Drugs Agency.

Amounts expressed in percent (%) refer to percent of weight, based on the total weight of the formulation (w/w) unless stated differently.

The invention will now be illustrated by the following examples without restricting it.

Example 1: Metered Dose Inhaler

A solution of 1.07 g ethanol and of 250 g TG 227 is liquified by cooling to a temperature of approx. -50°C in a stainless steel vessel. 1.428 g micronized Ciclesonide is transferred into the vessel and dispersed in the ethanol/propellant mixture using a high shear mixer. 200 g TG 227 is filled into a batching vessel and liquified by cooling to a temperature of approx. -50°C. 0.214 g micronized disodium cromoglycate is transferred into the batching vessel and dispersed using a high shear mixer. 0.043 g formoterol fumarate dihydrate is added to the chilled suspension. The suspension is further dispersed using the high shear mixer. The ciclesonide suspension in ethanol/TG227 is then transferred into the batching vessel. The suspension is homogenized for sufficient time to give a homogenous suspension. TG 227 is added to the suspension to a total weight of 500 g. While cooling and stirring the suspension is filled in aluminum cans and a 50µl metering valve is crimped into place. Each actuation of 70 mg delivers 200 µg of ciclesonide and 6 µg of formoterol fumarate.

Example 2: Metered Dose Inhaler

A solution of 1.07g ethanol and of 250 g TG 227 is liquified by cooling to a temperature of approx. -50°C in a stainless steel vessel. 1.428 g micronized Ciclesonide is transferred into the vessel and dispersed in the ethanol/propellant mixture using a high shear mixer. 200 g TG 227 is filled into a batching vessel and liquified by cooling to a temperature of approx. -50°C. 0.043 g formoterol fumarate dihydrate is transferred into the batching vessel and dispersed using a high shear mixer. The ciclesonide suspension in ethanol/TG227 is then transferred into the batching vessel. The suspension is homogenized for sufficient time to give a homogenous suspension. TG 227 is added to the suspension to a total weight of 500 g. While cooling and stirring the suspension is filled in aluminum cans and a 50µl metering valve is crimped into place. Each actuation of 70 mg delivers 200 µg of ciclesonide and 6 µg of formoterol fumarate.

Example 3: Metered Dose Inhaler

0.05g of oleic acid is dissolved in 1.07g ethanol. 250g of TG 227 are added and the mixture is liquified by cooling to a temperature of approx. -50 °C in a stainless steel vessel. 1.428 g micronized Ciclesonide is transferred into the vessel and dispersed in the ethanol/propellant mixture using a high shear mixer. 200 g TG 227 is filled into a batching vessel and liquified by cooling to a temperature of approx. -50°C. 0.043 g formoterol fumarate dihydrate is transferred into the batching vessel and dispersed using a high shear mixer. The ciclesonide suspension in ethanol/TG227 is then transferred into the batching vessel. The suspension is homogenized for sufficient time to give a homogenous suspension. TG 227 is added to the suspension to a total weight of 500 g. While cooling and stirring the suspension is filled in aluminum cans and a 50µl metering valve is crimped into place. Each actuation of 70 mg delivers 200 µg of ciclesonide and 6 µg of formoterol fumarate.

Although the invention has been described in terms of preferred formulations and ingredients, it will be understood that these are not intended to be limiting. To the contrary, those skilled in the art will understand that various optional ingredients may be included, such as flavouring agents, preservatives, additional active ingredients, and the like, while still embodying the present invention.

Claims

1. Pharmaceutical suspension formulation comprising
 - a. particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and
 - c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

2. Pharmaceutical suspension formulation according to claim 1 consisting of
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - c. ethanol,
 - d. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - e. optionally a surfactant.

3. Suspension formulation according to any of the preceding claims containing less than 3% by weight of ethanol.

4. Pharmaceutical suspension formulation according to claim 1 consisting of
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - c. a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - d. a surfactant.

5. Suspension formulation according to any of the preceding claims containing R,R-formoterol.

6. Suspension formulation according to any of the preceding claims containing formoterol fumarate dihydrate.

7. Suspension formulation according to any of the preceding claims containing oleic acid as surfactant.
8. Suspension formulation according to any of the preceding claims containing about 0.001 to 0.1 % (w/w) of oleic acid.
9. Suspension formulation according to any of the preceding claims containing HFA 227 as propellant.
10. Suspension formulation according to claim 1 containing disodium chromoglycate at concentrations, which are not therapeutically and/or prophylactically active.
11. Suspension formulation according to claim 1, which is administered in once daily dosing regimen.

INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/EP2004/051067

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/58 A61K31/167 A61K9/12
 //(A61K31/58,31:167)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 195 41 689 A (BYK GULDEN LOMBERG CHEM FAB) 15 May 1996 (1996-05-15) cited in the application claims; example 4	1-11
Y	WO 97/47286 A (JINKS PHILIP A ;OLIVER MARTIN J (GB); PALING SIMON G (GB); JAISWAL) 18 December 1997 (1997-12-18) cited in the application claims 1-10	1-11
Y	WO 93/11747 A (MINNESOTA MINING & MFG) 24 June 1993 (1993-06-24) cited in the application claim 10; example 3	1-11
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search 11 November 2004	Date of mailing of the international search report 22/11/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Herrera, S

INTERNATIONAL SEARCH REPORT

Inter	Application No
PCT/EP2004/051067	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/52542 A (MULLER HELGERT ;FATANIA KANU M (GB); OLIVER MARTIN J (GB); SCOTT J) 26 November 1998 (1998-11-26) cited in the application claims 1-4; examples 11,16 -----	1-11

INTERNATIONAL SEARCH REPORT

 Intern. Application No
 PCT/EP2004/051067

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19541689	A	15-05-1996	DE 19541689 A1	15-05-1996
WO 9747286	A	18-12-1997	AT 275940 T	15-10-2004
			AU 726382 B2	02-11-2000
			AU 3373997 A	07-01-1998
			CA 2257841 A1	18-12-1997
			DE 69730723 D1	21-10-2004
			EP 1400239 A1	24-03-2004
			EP 0934057 A1	11-08-1999
			ID 19520 A	16-07-1998
			JP 2000513340 T	10-10-2000
			NO 985720 A	11-02-1999
			NZ 333202 A	23-06-2000
			US 6054488 A	25-04-2000
			WO 9747286 A1	18-12-1997
			ZA 9704546 A	23-11-1998
WO 9311747	A	24-06-1993	AT 260641 T	15-03-2004
			AT 150296 T	15-04-1997
			AT 204743 T	15-09-2001
			AU 709052 B2	19-08-1999
			AU 1234297 A	20-03-1997
			AU 3272893 A	19-07-1993
			CA 2126244 A1	24-06-1993
			CA 2320129 A1	24-06-1993
			DE 69218455 D1	24-04-1997
			DE 69218455 T2	23-10-1997
			DE 69232034 D1	04-10-2001
			DE 69232034 T2	06-06-2002
			DE 69233319 D1	08-04-2004
			DK 1086688 T3	16-08-2004
			DK 617610 T3	06-10-1997
			DK 717987 T3	12-11-2001
			EP 1086688 A1	28-03-2001
			EP 0617610 A1	05-10-1994
			EP 0717987 A2	26-06-1996
			ES 2099415 T3	16-05-1997
			ES 2159678 T3	16-10-2001
			GR 3022874 T3	30-06-1997
			GR 3036467 T3	30-11-2001
			JP 7502275 T	09-03-1995
			JP 2004143183 A	20-05-2004
			NZ 246421 A	28-05-1996
			PT 1086688 T	30-06-2004
			PT 717987 T	28-12-2001
			WO 9311747 A1	24-06-1993
			US 2003103907 A1	05-06-2003
			US 6743413 B1	01-06-2004
			US 2004013611 A1	22-01-2004
			US 2004197273 A1	07-10-2004
WO 9852542	A	26-11-1998	AT 245966 T	15-08-2003
			AU 726835 B2	23-11-2000
			AU 7496298 A	11-12-1998
			BG 64268 B1	31-08-2004
			BG 103902 A	31-05-2000
			BR 9809448 A	20-06-2000
			CA 2290521 A1	26-11-1998

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051067

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9852542	A	CN 1257421 T	21-06-2000
		DE 69816811 D1	04-09-2003
		DE 69816811 T2	15-04-2004
		DK 983058 T3	24-11-2003
		EA 2381 B1	25-04-2002
		EP 0983058 A1	08-03-2000
		ES 2205491 T3	01-05-2004
		HU 0002691 A2	28-02-2001
		JP 2001526685 T	18-12-2001
		NO 995667 A	18-11-1999
		NZ 500874 A	28-09-2001
		PL 336885 A1	17-07-2000
		PT 983058 T	31-12-2003
		SI 983058 T1	29-02-2004
		SK 157699 A3	16-05-2000
		TR 9902863 T2	22-05-2000
		US 6120752 A	19-09-2000
		WO 9852542 A1	26-11-1998
